B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 600 KRW -2.13% Market Closed
Market Cap: 469.1B KRW
Have any thoughts about
BioNote Inc?
Write Note

Wall Street
Price Targets

Price Targets Summary
BioNote Inc

Wall Street analysts forecast BioNote Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BioNote Inc is 5 814 KRW with a low forecast of 5 757 KRW and a high forecast of 5 985 KRW.

Lowest
Price Target
5 757 KRW
25% Upside
Average
Price Target
5 814 KRW
26% Upside
Highest
Price Target
5 985 KRW
30% Upside
BioNote Inc Competitors:
Price Targets
LTRN
Lantern Pharma Inc.
633% Upside
ORY
Oryzon Genomics SA
296% Upside
LGND
Ligand Pharmaceuticals Inc
8% Upside
CAPR
Capricor Therapeutics Inc
116% Upside
BMRN
Biomarin Pharmaceutical Inc
55% Upside
VCEL
Vericel Corp
7% Upside
SIGHT
Gensight Biologics SA
22% Upside
002252
Shanghai RAAS Blood Products Co Ltd
7% Downside

Revenue
Forecast

Revenue Estimate
BioNote Inc

For the last 3 years the compound annual growth rate for BioNote Inc's revenue is -48%. The projected CAGR for the next 3 years is 30%.

-48%
Past Growth
30%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
BioNote Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
BioNote Inc

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BioNote Inc's stock price target?
Price Target
5 814 KRW

According to Wall Street analysts, the average 1-year price target for BioNote Inc is 5 814 KRW with a low forecast of 5 757 KRW and a high forecast of 5 985 KRW.

What is BioNote Inc's Revenue forecast?
Projected CAGR
30%

For the last 3 years the compound annual growth rate for BioNote Inc's revenue is -48%. The projected CAGR for the next 3 years is 30%.

Back to Top